Octreotide and Insulin Glulisine Interaction

Drug interaction information between Octreotide and Insulin Glulisine.

Octreotide and Insulin Glulisine have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Octreotide and Insulin Glulisine. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Octreotide

Somatostatin Analog

Drug B

Insulin Glulisine

Rapid-Acting Insulin

How They Interact

Octreotide can increase the risk of low blood sugar when taken with insulin.

FDA Label Information

7 DRUG INTERACTIONS Table 6: Clinically Significant Drug Interactions with APIDRA Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.

Insulin Glulisine Also Interacts With

View all Insulin Glulisine interactions →

Frequently Asked Questions

What SPL severity band is on file for Octreotide + Insulin Glulisine?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Octreotide has 14 labeled pairs on file vs Insulin Glulisine's 9. In the moderate band specifically: Octreotide has 9 (also Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine); Insulin Glulisine has 3 (also Fluoxetine, Pramlintide).

What mechanism field is on file for Octreotide and Insulin Glulisine?

Octreotide can increase the risk of low blood sugar when taken with insulin.

Octreotide's labeled portfolio outnumbers Insulin Glulisine

SPL source-record counts only. This page's band is moderate · classes on file: Octreotide (Somatostatin Analog); Insulin Glulisine (Rapid-Acting Insulin).

Octreotide

0 major · 9 moderate · 5 minor · 14 total

Insulin Glulisine

0 major · 3 moderate · 6 minor · 9 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.